Myriad Genetics, Abbott deal

Myriad will use its BRACAnalysis test to detect mutations in breast cancer 1 early onset (BRCA1) and BRCA2 genes in patients to be enrolled in Abbott's Phase III trial of an undisclosed poly(ADP-r...